James Kihara Sells 4,084 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 4,084 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total value of $96,749.96. Following the completion of the transaction, the insider directly owned 25,058 shares of the company’s stock, valued at approximately $593,624.02. This represents a 14.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

ACADIA Pharmaceuticals Stock Down 2.9%

NASDAQ:ACAD traded down $0.70 on Wednesday, reaching $23.10. 1,449,537 shares of the company’s stock were exchanged, compared to its average volume of 2,140,009. The firm has a market capitalization of $3.91 billion, a price-to-earnings ratio of 17.37, a price-to-earnings-growth ratio of 7.90 and a beta of 0.80. ACADIA Pharmaceuticals Inc. has a 52-week low of $13.40 and a 52-week high of $26.65. The business has a fifty day moving average of $22.37 and a 200-day moving average of $22.44.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.14 by $0.28. ACADIA Pharmaceuticals had a net margin of 21.80% and a return on equity of 14.69%. The business had revenue of $278.63 million during the quarter, compared to analyst estimates of $276.52 million. During the same quarter last year, the firm posted $0.20 earnings per share. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current year.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of ACADIA Pharmaceuticals by 9.0% during the 1st quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company’s stock worth $252,526,000 after buying an additional 1,255,594 shares during the last quarter. Geode Capital Management LLC grew its position in shares of ACADIA Pharmaceuticals by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 3,024,097 shares of the biopharmaceutical company’s stock valued at $65,238,000 after buying an additional 69,584 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in ACADIA Pharmaceuticals by 16.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,798,134 shares of the biopharmaceutical company’s stock worth $59,712,000 after acquiring an additional 402,534 shares in the last quarter. Fred Alger Management LLC raised its stake in ACADIA Pharmaceuticals by 2.0% during the 1st quarter. Fred Alger Management LLC now owns 2,769,828 shares of the biopharmaceutical company’s stock worth $46,007,000 after acquiring an additional 54,899 shares in the last quarter. Finally, First Trust Advisors LP lifted its position in ACADIA Pharmaceuticals by 2.8% in the second quarter. First Trust Advisors LP now owns 2,434,376 shares of the biopharmaceutical company’s stock valued at $52,509,000 after acquiring an additional 65,914 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ACAD. Cowen reaffirmed a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, September 11th. Mizuho boosted their target price on ACADIA Pharmaceuticals from $23.00 to $24.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. Weiss Ratings restated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a report on Tuesday, October 14th. Wall Street Zen raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, TD Cowen lifted their price objective on ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $28.83.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.